Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

NCT06761599 | Active Not Recruiting DMC

• 1 other identifier: MSAHS/Batch-Spring23/046
• Study Type: observational
• Target: 214
• Locations: 1 country
• Sites: 1

Brief Summary

Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.

Conditions

Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• high-resolution computed tomography

  An HRCT (high-resolution computed tomography) scan is a type of CT scan healthcare providers use to get detailed images of your lungs. Providers most commonly use it to diagnose and monitor interstitial lung diseases and conditions that affect your small airways and alveoli (air sacs).

  12 Months

Interventions

group 1 DIAGNOSTIC_TEST

To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

to check the Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

You may qualify if:

• Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment.
• Patients of all ages and both genders.
• Patients with histologically confirmed HL, as per the WHO 2016 classification.
• Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course.
• Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details.

You may not qualify if:

• Patients with a diagnosis of another malignancy.
• Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments.
• Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis.
• Patients who are unable to complete pulmonary function tests.

Sponsors & Collaborators

• Superior University: lead

Study Sites (1)

Shaukat Khanum Memorial Cancer Hospital and Research Centre, 5-B, Sector A2, Phase 5, Hayatabad

Peshawar, Khyber Pakhtunkhwa, Pakistan

Location

MeSH Terms

Conditions

Hodgkin Disease

Interventions

Chromosomes, Human, 1-3

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Chromosomes, Human; Chromosomes, Mammalian; Chromosomes; Genetic Structures; Genetic Phenomena

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 19, 2024
• First Posted: January 7, 2025
• Study Start: February 18, 2024
• Primary Completion: July 15, 2024
• Study Completion: March 1, 2025
• Last Updated: January 7, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)